ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer

Immunotherapy with checkpoint inhibitors (CI) represents an important novel development in cancer treatment. Metastatic triple-negative breast cancer (mTNBC) is incurable, with a median survival of only  ~ 13 m...

Source: Journal of Translational Medicine - June 23, 2020 Category: Research Authors: J. A. Kyte, A. R øssevold, R. S. Falk and B. Naume Tags: Protocol Source Type: research